Shanghai Henlius Biotech Receives Approval in Australia for Phase 2/3 Trial of HLX07 and HANSIZHUANG Combination Therapy for Advanced Lung Cancer 1
Shanghai Henlius Biotech Announces Approval of Phase 2/3 Cli...
Sign in to continue:
Shanghai Henlius Biotech Announces Approval of Phase 2/3 Cli...
Nexteer Automotive Group Limited Announces Record Financial ...
First Shanghai Investments Limited 2025 Annual Report: Key H...
Key Highlights for Investors Date of Board Meeting: ...
Tianli Holdings Group Limited 2025 Annual Report – Key Inves...
CaoCao Inc. 2025 Annual Report: Key Insights and Shareholder...
Edvance International Unveils AI Cybersecurity Tech Hub and ...
SMC Electric Limited 2025 Annual Report: Key Insights for In...
Mount Everest Gold Group 2025 Annual Report: Key Highlights ...
Alpha Professional Holdings Announces Voluntary Winding-Up o...